Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006.

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Abstract Text:

Benjamin Djulbegovic,Ambuj Kumar,Heloisa P Soares,Iztok Hozo,Gerold Bepler,Mike Clarke,Charles L Bennett,

BACKGROUND: The evaluation of research output, such as estimation of the proportion of treatment successes, is of ethical, scientific, and public importance but has rarely been evaluated systematically. We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions. METHODS: We extracted data from all completed (published and unpublished) phase 3 RCTs conducted by the National Cancer Institute cooperative groups since their inception in 1955. Therapeutic successes were determined by (1) assessing the proportion of statistically significant trials favoring new or standard treatments, (2) determining the proportion of the trials in which new treatments were considered superior to standard treatments according to the original researchers, and (3) quantitatively synthesizing data for main clinical outcomes (overall and event-free survival). RESULTS: Data from 624 trials (781 randomized comparisons) involving 216 451 patients were analyzed. In all, 30% of trials had statistically significant results, of which new interventions were superior to established treatments in 80% of trials. The original researchers judged that the risk-benefit profile favored new treatments in 41% of comparisons (316 of 766). Hazard ratios for overall and event-free survival, available for 614 comparisons, were 0.95 (99% confidence interval [CI], 0.93-0.98) and 0.90 (99% CI, 0.87- 0.93), respectively, slightly favoring new treatments. Breakthrough interventions were discovered in 15% of trials. CONCLUSIONS: Approximately 25% to 50% of new cancer treatments that reach the stage of assessment in RCTs will prove successful. The pattern of successes has become more stable over time. The results are consistent with the hypothesis that the ethical principle of equipoise defines limits of discoverability in clinical research and ultimately drives therapeutic advances in clinical medicine.

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Publishing Authors By Initials

B Djulbegovic,A Kumar,HP Soares,I Hozo,G Bepler,M Clarke,CL Bennett,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of internal medicine

VOLUME: 168

Page Numbers: 632-42

Journal Abbreviation: Arch. Intern. Med.

ISSN: 0003-9926

DAY: 24

MONTH: Mar

YEAR: 2008

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372440

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006.

AFFILIATION: H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612. benjamin.djulbegovic@moffitt.org.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006 Related Publications

• Activation of platelet alphaIIbbeta3 by an exogenous peptide corresponding to the transmembrane domain of alphaIIb.
• Body mass index in older persons is associated with Alzheimer disease pathology.
• Change in motor function and risk of mortality in older persons.
• Chronic psychological distress and risk of Alzheimer's disease in old age.
• Cognitive decline in old age: separating retest effects from the effects of growing older.
• Diabetes is related to cerebral infarction but not to AD pathology in older persons.
• Diabetes mellitus, dementia, and cognitive function in older persons.
• Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm.
• Effects of aquatic exercise on flexibility, strength and aerobic fitness in adults with osteoarthritis of the hip or knee.
• Elder abuse.
• Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells.
• Experimental evidence for a metallohydrolase mechanism in which the nucleophile is not delivered by a metal ion: EPR spectrokinetic and structural studies of aminopeptidase from Vibrio proteolyticus.
• Genetic and environmental factors associated with incidence of infectious bovine keratoconjunctivitis in preweaned beef calves.
• Harm avoidance and disability in old age.
• Imaging oxygen pressure in the rodent retina by phosphorescence lifetime.
• In cis autosomal dominant mutation of Senataxin associated with tremor/ataxia syndrome.
• Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating.
• Loneliness and risk of Alzheimer disease.
• Memory complaints are related to Alzheimer disease pathology in older persons.
• Memory for facial expressions: the power of a smile.
• Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease.
• Personality and incident disability in older persons.
• Physical activity and motor decline in older persons.
• Physical activity is associated with incident disability in community-based older persons.
• Plant genome values: how much do we know?
• Postmortem indices linking risk factors to cognition: results from the Religious Order Study and the Memory and Aging Project.
• Quantitative determination of uracil residues in Escherichia coli DNA: Contribution of ung, dug, and dut genes to uracil avoidance.
• Serotonin facilitates a persistent calcium current in motoneurons of rats with and without chronic spinal cord injury.
• The GLH proteins, Caenorhabditis elegans P granule components, associate with CSN-5 and KGB-1, proteins necessary for fertility, and with ZYX-1, a predicted cytoskeletal protein.
• Unusual skin and testicular lesions in a patient with CMML.